Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-Β activation

Laboratory Investigation

Volumn 90, Issue 7, 2010, Pages 1078-1090

  Fitchev, Philip P ^a   Wcislak, Susan M ^a   Lee, Chung ^b   Bergh, Anders ^c   Brendler, Charles B ^a   Stellmach, Veronica M ^b   Crawford, Susan E ^a   Mavroudis, Constantine D ^b   Cornwell, Mona L ^a   Doll, Jennifer A ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

angiogenesis; cancer; prostate; thrombospondin 1; transforming growth factor ; vascular endothelial growth factor

Indexed keywords

ANDROGEN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANDROSTANOLONE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CASTRATION; CELL CULTURE; CELL HYPOXIA; CELL INTERACTION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; STROMA CELL; ANIMAL; ANOXIA; C57BL MOUSE; CARCINOMA; CELL LINE; EPITHELIUM CELL; HYPERPLASIA; METABOLISM; ORCHIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; SECRETION;

ANDROGENS; ANIMALS; ANOXIA; CARCINOMA; CELL LINE; DIHYDROTESTOSTERONE; EPITHELIAL CELLS; HUMANS; HYPERPLASIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; ORCHIECTOMY; PHENOTYPE; PROSTATE; PROSTATIC NEOPLASMS; STROMAL CELLS; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 77954147694     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.90     Document Type: Article

References (39)

1. Lissbrant IF, Stattin P, Damber JE, et al. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33: 38-45.
2. Silberman MA, Partin AW, Veltri RW, et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5-7 adenocarcinoma of the prostate. Cancer 1997;79:772-779.
3. Mehta R, Kyshtoobayeva A, Kurosaki T, et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001;7:81-88.
4. Kwak C, Jin RJ, Lee C, et al. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002;89: 303-309.
5. Doll JA, Reiher FK, Crawford SE, et al. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
6. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-780.
7. Franck-Lissbrant I, Haggstrom S, Damber JE, et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998;139:451-456.
8. Lekas E, Johansson M, Widmark A, et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25:309-314.
9. Lekas E, Engstrand C, Bergh A, et al. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999;27:174-179.
10. Shabsigh A, Chang DT, Heitjan DF, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201-206.
11. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-10825.
12. Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507-2511.
13. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998;251:287-290. (Pubitemid 28498104)
14. Shibata Y, Kashiwagi B, Arai S, et al. Direct regulation of prostate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo. Endocrinology 2004;145:4507-4512.
15. Prins GS, Birch L. Immunocytochemical analysis of androgen receptor along the ducts of the separate rat prostate lobes after androgen withdrawal and replacement. Endocrinology 1993;132:169-178.
16. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991;129:3187-3199.
17. Levine AC, Liu XH, Greenberg PD, et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998;139:4672-4678.
18. Shabsigh A, Ghafar MA, de la Taille A, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001;81:437-444.
19. Rudolfsson SH, Bergh A. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol 2008;196:11-19.
20. Rudolfsson SH, Bergh A. Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 2009;13:219-225.
21. Colombel M, Filleur S, Fournier P, et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 2005;65:300-308.
22. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008;65:700-712.
23. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159-1170.
24. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 1994;269:26783-26788.
25. Yehualaeshet T, O'Connor R, Green-Johnson J, et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999;155:841-851.
26. Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009;13:227-234.
27. Wikstrom P, Westin P, Stattin P, et al. Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 1999;38:268-277.
28. Danielpour D. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 1996;166: 231-239.
29. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-1415.
30. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-6628.
31. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
32. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998;101:982-992.
33. Berger AP, Kofler K, Bektic J, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003;57:57-65.
34. Matsushima H, Goto T, Hosaka Y, et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999;85:1822-1827.
35. Montironi R, Diamanti L, Thompson D, et al. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol 1996;30:191-200.
36. Shafer MW, Mangold L, Partin AW, et al. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Prostate 2007;67:255-267.
37. Bastian M, Steiner M, Schuff-Werner P. Expression of thrombospondin-1 in prostate-derived cell lines. Int J Mol Med 2005;15:49-56.
38. Jin RJ, Kwak C, Lee SG, et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000;7:1537-1542.
39. Quesada AJ, Nelius T, Yap R, et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005;12:649-658.